Docoh
Loading...

CRNX Crinetics Pharmaceuticals

News

From Benzinga Pro
52 Biggest Movers From Yesterday
1 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021
30 Nov 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
JMP Securities Initiates Coverage On Crinetics Pharmaceuticals with Market Outperform Rating, Announces Price Target of $43
30 Nov 21
News, Price Target, Initiation, Analyst Ratings
JMP Securities analyst Jonathan Wolleben initiates coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform rating and announces Price Target of $43.
12 Health Care Stocks Moving In Friday's Intraday Session
26 Nov 21
Intraday Update, Markets, Movers
Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021
23 Nov 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Evercore ISI Group Initiates Coverage On Crinetics Pharmaceuticals with Outperform Rating, Announces Price Target of $68
23 Nov 21
News, Price Target, Initiation, Analyst Ratings
Evercore ISI Group analyst Maneka Mirchandaney initiates coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform rating and announces Price Target of $68.
Crinetics Pharmaceuticals Presenting New Data From Open Label Extension Trial Of Paltusotine In Acromegaly At Society For Endocrinology BES Congress
8 Nov 21
News, FDA, Events
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and
10 Biggest Price Target Changes For Monday
8 Nov 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Barclays cut Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) price target from $50 to $11. Deciphera Pharmaceuticals shares rose 7.1% to $9.45 in pre-market trading.
HC Wainwright & Co. Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $35
8 Nov 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Douglas Tsao maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and raises the price target from $30 to $35.
Crinetics Pharmaceuticals Q3 EPS $(0.73) Down From $(0.56) YoY
5 Nov 21
Earnings, News
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(0.73) per share. This is a 30.36 percent decrease over losses of $(0.56) per share from the same period last year.
Last Week's Notable Insider Buys: Beacon Roofing Supply, Enfusion, Nerdy And More
30 Oct 21
News, Small Cap, Insider Trades
Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain or near highs. Beneficial owners made some the most notable insider purchases last week. Some insiders took advantage of public offerings of shares as well.
54 Biggest Movers From Yesterday
22 Oct 21
News, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) shares climbed 356.8% to close at $45.50 on Thursday following an announcement the company will merge with Trump Media & Technology Group.
12 Health Care Stocks Moving In Thursday's Intraday Session
21 Oct 21
Intraday Update, Markets, Movers
38 Stocks Moving In Thursday's Mid-Day Session
21 Oct 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) shares jumped 132.3% to $23.14 following an announcement the company will merge with Trump Media & Technology Group.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
21 Oct 21
Pre-Market Outlook, Markets, Movers
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
21 Oct 21
Biotech, Earnings, News, Penny Stocks, Health Care, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Crinetics Spins Off Radiopharmaceuticals Efforts Into New Company
19 Oct 21
Biotech, News, Health Care, Financing, Offerings, Small Cap, General
Radionetics Oncology Emerges From Crinetics Pharmaceuticals With A Platform And Deep Pipeline Of Nonpeptide Targeted Radiopharmaceutical Drug Candidates For Precision Oncology
18 Oct 21
News
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel nonpeptide therapeutics for rare endocrine diseases and
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
16 Sep 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15)
Crinetics Pharmaceuticals' Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept With Strong Dose-dependent Suppression Of Insulin Secretion In Phase 1 Single Ascending Dose Study
15 Sep 21
Biotech, General
CRN04777 Phase 1 Program Progressing to Multiple Ascending Dose Cohorts to Advance Development as a Treatment for Congenital Hyperinsulinisms Demonstrated Dose-dependent Reductions in Glucose-stimulated and

Press releases

From Benzinga Pro
Crinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
18 Nov 21
News, Press Releases
SAN DIEGO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
25 Oct 21
News, IPOs, Markets, Press Releases
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
21 Oct 21
Markets, Press Releases
SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
20 Oct 21
Markets, Press Releases
SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for
Radionetics Oncology Emerges from Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted Radiopharmaceutical Drug Candidates for Precision Oncology
18 Oct 21
Press Releases, General
Co-founded by Crinetics, 5AM Ventures and Frazier Healthcare Partners, the New Company Launches with $30M in Initial Financing Provided by 5AM and Frazier Pipeline is Built from Crinetics' Core Nonpeptide Platform and
Crinetics Pharmaceuticals to Unveil its Parathyroid Hormone Receptor Antagonist Program at the American Society for Bone and Mineral Research Annual Meeting
27 Sep 21
News, Analyst Ratings, Press Releases
- Late-breaking Poster Presentation on Sunday, October 3, 2021 SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the
Crinetics Pharmaceuticals' Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study
15 Sep 21
Health Care, Press Releases, General
CRN04777 Phase 1 Program Progressing to Multiple Ascending Dose Cohorts to Advance Development as a Treatment for Congenital Hyperinsulinisms Demonstrated Dose-dependent Reductions in Glucose-stimulated and
Crinetics Pharmaceuticals to Participate in September Investor Conferences
7 Sep 21
News, Health Care, Press Releases
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (NASDAQ:CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare